Anders Martin-Löf
Finanzdirektor/CFO bei BIOARCTIC AB
Vermögen: 15 197 $ am 30.04.2024
Aktive Positionen von Anders Martin-Löf
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CANTARGIA AB | Direktor/Vorstandsmitglied | 01.01.2018 | - |
Independent Dir/Board Member | 01.01.2018 | - | |
BIOARCTIC AB | Finanzdirektor/CFO | 01.06.2023 | - |
Unternehmenssekretär | 01.06.2023 | - | |
Lisa Martin-Löf Konsultbyrå AB | Direktor/Vorstandsmitglied | - | - |
Oncopeptides Incentive AB | Direktor/Vorstandsmitglied | - | - |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Anders Martin-Löf
Ehemalige bekannte Positionen von Anders Martin-Löf
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ONCOPEPTIDES AB | Finanzdirektor/CFO | 01.11.2018 | 08.11.2021 |
RAYSEARCH LABORATORIES AB | Finanzdirektor/CFO | 01.01.2007 | 02.07.2015 |
Investor Relations Kontakt | 01.01.2007 | 02.07.2015 | |
Public Communications Contact | 04.12.2014 | 02.07.2015 | |
A3P Biomedical AB
A3P Biomedical AB Medical/Nursing ServicesHealth Services A3P Biomedical AB is a Swedish company that aims to improve the precision in prostate cancer diagnostics and treatment. A3P Biomedical is headquartered in Sweden and has subsidiaries in the country. The private company's lead product is Stockholm3, a blood test for early detection of aggressive prostate cancer. The test has been developed by scientists at Institutet and validated in clinical studies involving more than 80,000 men. A total of SEK 750 million has been invested in clinical research, product development, and market validation activities. The company sells Stockholm3 to healthcare providers through direct sales and distributors. | Finanzdirektor/CFO | - | - |
SWEDISH ORPHAN BIOVITRUM AB | Investor Relations Kontakt | - | - |
░░░░░░░ ░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | - | - |
░░░░░░░░░░ ░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░░░ ░░ | ░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
Ausbildung von Anders Martin-Löf
Royal Institute of Technology | Graduate Degree |
ENSIMAG | Graduate Degree |
University of Stockholm | Undergraduate Degree |
Statistik
International
Schweden | 16 |
Frankreich | 2 |
Operativ
Director of Finance/CFO | 6 |
Director/Board Member | 5 |
Public Communications Contact | 3 |
Sektoral
Health Technology | 7 |
Consumer Services | 4 |
Technology Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 5 |
---|---|
RAYSEARCH LABORATORIES AB | Technology Services |
SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
CANTARGIA AB | Health Technology |
ONCOPEPTIDES AB | Health Technology |
BIOARCTIC AB | Health Technology |
Private Unternehmen | 8 |
---|---|
Biovitrum AB
Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Commercial Services |
Wilson Therapeutics AB
Wilson Therapeutics AB Pharmaceuticals: MajorHealth Technology Wilson Therapeutics AB engages in the development of novel therapies for patients with rare copper-mediated disorders. The company was founded on April 25, 2012 and is headquartered in Stockholm, Sweden. | Health Technology |
Sciencecap Stockholm AB | |
Extenda AB
Extenda AB Information Technology ServicesTechnology Services Extenda AB develops point-of-sale technology (POS) solutions. Its product suite include transaction engine, selfscan, mobile POS, and self checkout. The firm also offers support, service and maintenance, and catalogue services. The company was founded by Peter Carlman in 1982 and is headquartered in Stockholm, Sweden. | Technology Services |
Lisa Martin-Löf Konsultbyrå AB | |
Oncopeptides Incentive AB | |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | Health Technology |
A3P Biomedical AB
A3P Biomedical AB Medical/Nursing ServicesHealth Services A3P Biomedical AB is a Swedish company that aims to improve the precision in prostate cancer diagnostics and treatment. A3P Biomedical is headquartered in Sweden and has subsidiaries in the country. The private company's lead product is Stockholm3, a blood test for early detection of aggressive prostate cancer. The test has been developed by scientists at Institutet and validated in clinical studies involving more than 80,000 men. A total of SEK 750 million has been invested in clinical research, product development, and market validation activities. The company sells Stockholm3 to healthcare providers through direct sales and distributors. | Health Services |
- Börse
- Insiders
- Anders Martin-Löf
- Erfahrung